Daniele Pastori1, Pasquale Pignatelli1, Mirella Saliola1, Roberto Carnevale2, Tommasa Vicario1, Maria Del Ben1, Roberto Cangemi1, Francesco Barillà3, Gregory Y H Lip4, Francesco Violi5. 1. I Clinica Medica, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy. 2. I Clinica Medica, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy; Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. 3. Department of the Heart and Great Vessels Attilio Reale, "Sapienza" University of Rome, Rome, Italy. 4. University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK. 5. I Clinica Medica, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy. Electronic address: francesco.violi@uniroma1.it.
Abstract
BACKGROUND: Time in therapeutic range (TTR) reflects the quality of anticoagulation and is inversely correlated with ischemic stroke in atrial fibrillation (AF) patients. Few data on the relationship between TTR and myocardial infarction (MI) are available. We investigated the association between TTR and Major Adverse Cardiovascular Events (MACE) in a cohort of anticoagulated AF patients. METHODS: We calculated TTR for 627 AF patients on vitamin K antagonists, who were followed for a median of 30.8 months (1755 patients/year). The primary outcome was a combined endpoint of MACE including fatal/nonfatal MI and cardiovascular death. RESULTS: Mean age was 73.3 (±8.2) years, and 40.2% were women. During follow-up, we recorded 67 events: 19 stroke/TIA (1.1%/year) and 48 MACE (2.9%/year): 24 MI and 24 cardiovascular deaths. The cohort was categorized according to tertiles of TTR values: TTR 13-58%, 59-74%, and 75-100%. There was a significant increased rate of MACE across tertiles of TTR (Log-Rank test: p<0.001). On Cox proportion hazard analysis, the 2nd vs. 1st tertile of TTR (p=0.002, hazard ratio [HR] 0.347, confidence interval [CI] 95% 0.177-0.680), 3rd vs. 1st tertile of TTR (p<0.001, HR 0.164, CI 95% 0.067-0.402), age (p<0.001, HR 1.094, CI 95% 1.042-1.148), history of stroke/TIA (p=0.015, HR 2.294, CI 95% 1.172-4.490) and smoking (p=0.003, HR 3.450, CI 95% 1.532-7.769) predicted MACE. CONCLUSION: TTR was an independent predictor of MACE in our cohort of AF patients. Our findings suggest that a good anticoagulation control is necessary to reduce not only the risk of stroke but also that of MACE.
BACKGROUND: Time in therapeutic range (TTR) reflects the quality of anticoagulation and is inversely correlated with ischemic stroke in atrial fibrillation (AF) patients. Few data on the relationship between TTR and myocardial infarction (MI) are available. We investigated the association between TTR and Major Adverse Cardiovascular Events (MACE) in a cohort of anticoagulated AFpatients. METHODS: We calculated TTR for 627 AFpatients on vitamin K antagonists, who were followed for a median of 30.8 months (1755 patients/year). The primary outcome was a combined endpoint of MACE including fatal/nonfatal MI and cardiovascular death. RESULTS: Mean age was 73.3 (±8.2) years, and 40.2% were women. During follow-up, we recorded 67 events: 19 stroke/TIA (1.1%/year) and 48 MACE (2.9%/year): 24 MI and 24 cardiovascular deaths. The cohort was categorized according to tertiles of TTR values: TTR 13-58%, 59-74%, and 75-100%. There was a significant increased rate of MACE across tertiles of TTR (Log-Rank test: p<0.001). On Cox proportion hazard analysis, the 2nd vs. 1st tertile of TTR (p=0.002, hazard ratio [HR] 0.347, confidence interval [CI] 95% 0.177-0.680), 3rd vs. 1st tertile of TTR (p<0.001, HR 0.164, CI 95% 0.067-0.402), age (p<0.001, HR 1.094, CI 95% 1.042-1.148), history of stroke/TIA (p=0.015, HR 2.294, CI 95% 1.172-4.490) and smoking (p=0.003, HR 3.450, CI 95% 1.532-7.769) predicted MACE. CONCLUSION: TTR was an independent predictor of MACE in our cohort of AFpatients. Our findings suggest that a good anticoagulation control is necessary to reduce not only the risk of stroke but also that of MACE.
Authors: Marcelo Sanmartín Fernández; Manuel Anguita Sánchez; Fernando Arribas; Gonzalo Barón-Esquivias; Vivencio Barrios; Juan Cosin-Sales; María Asunción Esteve-Pastor; Roman Freixa-Pamias; Iñaki Lekuona; Alejandro I Pérez-Cabeza; Isabel Ureña; José Manuel Vázquez Rodríguez; Carles Rafols Priu; Francisco Marin Journal: Cardiol J Date: 2022-05-27 Impact factor: 3.487
Authors: Valeria Raparelli; Daniele Pastori; Serena Francesca Pignataro; Anna Rita Vestri; Pasquale Pignatelli; Roberto Cangemi; Marco Proietti; Giovanni Davì; William Robert Hiatt; Gregory Yoke Hong Lip; Gino Roberto Corazza; Francesco Perticone; Francesco Violi; Stefania Basili Journal: Intern Emerg Med Date: 2018-03-26 Impact factor: 3.397
Authors: Leiliane Rodrigues Marcatto; Luciana Sacilotto; Francisco Carlos da Costa Darrieux; Denise Tessariol Hachul; Maurício Ibrahim Scanavacca; Jose Eduardo Krieger; Alexandre Costa Pereira; Paulo Caleb Junior Lima Santos Journal: Oncotarget Date: 2016-08-23
Authors: John K Bartoli-Abdou; Jignesh P Patel; Rosa Xie; Olubanke Dzahini; Bipin Vadher; Alison Brown; Lara N Roberts; Raj K Patel; Roopen Arya; Vivian Auyeung Journal: Res Pract Thromb Haemost Date: 2018-06-07